Top COVID-19 Deals (Part III): Biopharma and Govt. Institutions

The emergence of the coronavirus SARS-CoV-2 and the COVID-19 pandemic has spurred global healthcare and life sciences companies- as well as government agencies- to partner at unprecedented speed to develop vaccines- treatments- and kits This article covers the last six months of deal data provided by Chris Dokomajilar of DealForma During the last six months…

ByPrince GiriJune 26, 2020

TOP 20

Top 20 Biopharma Acquisitions of 2018 Based on the Total Deal Value

Biopharma acquisition activity in 2018 shows a significant increase over the previous year. Takeda proved to be on top with the acquisition of Shire among the top 20 acquisitions with a total deal value of $57.17B strengthening its capabilities in gastroenterology- neuroscience- oncology- rare diseases- and plasma-derived therapies. This article is based on the 2018…

ByPrince GiriSeptember 27, 2019

Top COVID-19 Deals (Part III): Biopharma and Govt. Institutions

Top 20 Biopharma Acquisitions of 2018 Based on the Total Deal Value

Contact US

OUR INFORMATION

FOLLOW US